ATLAS News · Companies

Novo Nordisk Presents REDEFINE 9 Results for CagriSema at ObesityWeek

Published November 14, 2026 · 3 sources

Novo Nordisk reports phase 3 REDEFINE 9 results for CagriSema, with about 21% average weight loss at lower doses, per PR Newswire.

What happened

Novo Nordisk announced primary results from the phase 3 REDEFINE 9 trial of its investigational drug CagriSema, according to a PR Newswire release. The data were presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology.

PR Newswire describes CagriSema as a fixed-dose combination of a GLP-1 and an amylin analog. The release says lower doses of the drug led to average weight loss of about 21% in the trial.

Separately, The Motley Fool published a comparison of Novo Nordisk and Pfizer, noting that Novo's position in obesity drugs faces rising rivals. Kalkine Media also ran a piece on what the company could reveal in its next quarterly results.

Context

GLP-1 and amylin-based therapies are a major focus of the obesity drug market, where several large drugmakers are developing competing treatments.

Why it matters

Trial data for a key obesity candidate can shape how investors view Novo Nordisk's pipeline and its competitive position in the obesity market.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

Novo Nordisk A/SNVO

+2.41%

Healthcare · NYSE

Live price

$41.63

live price · USD

Latest close before this story: $41.63+2.41% vs. previous close ($40.65) · November 13
Fair value (ATLAS): $79.90Fair range: $51.36 to $103.84The price ($41.63) is 47.9% below that figure.
Chance of a rise in 1 month: 50%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $39.22 and $44.25; 9 in 10, between $35.25 and $49.24.

See the full ATLAS analysis of Novo Nordisk A/S →

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology · PR Newswire · November 14, 2026
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027? · The Motley Fool · November 14, 2026
What Could Novo Nordisk (NYSE:NVO) Reveal in Its Next Quarterly Results? · Kalkine Media · November 15, 2026

Latest market news · Markets today on ATLAS · Novo Nordisk A/S

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer